DAPAGLIFLOZIN AS A CARDIORENAL PROTECTION STRATEGY IN CHRONIC KIDNEY DISEASE AND HEART FAILURE

Abstract

Chronic kidney disease and heart failure often coexist and influence each other reciprocally, increasing the complexity of clinical management and the risk of unfavorable outcomes. In this context, dapagliflozin has attracted attention not only for its glucose-lowering effect, but mainly for the benefits observed in renal and cardiovascular outcomes. This study aimed to analyze the most recent evidence on the role of dapagliflozin as a cardiorenal protection strategy in patients with chronic kidney disease and heart failure. This is an integrative literature review based on searches in PubMed/MEDLINE, Scopus, Web of Science, Embase, and LILACS, considering original articles published between April 2021 and April 2026. Studies directly addressing renal, cardiovascular, or cardiorenal outcomes related to the use of dapagliflozin were included. In the end, eight original studies composed the qualitative synthesis. Overall, the findings show that dapagliflozin contributes to slowing kidney disease progression, reducing the rate of renal function decline, and decreasing clinically relevant heart failure events, including in individuals without diabetes. It is concluded that dapagliflozin has been consolidating itself as a relevant therapeutic strategy in cardiorenal care, with benefits that go beyond glycemic control and reinforce its applicability in contemporary clinical practice.